Top

Published in:

01-05-2015 | Original article

CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma

Authors: Dr. med. Federico Collettini, Nadja Schreiber, Dr. med. Dirk Schnapauff, Priv.-Doz. Dr. med. Timm Denecke, Prof. Dr. med. Peter Wust, Prof. Dr. med. Eckart Schott, Prof. Dr. med. Bernd Hamm, Prof. Dr. med. Bernhard Gebauer

Published in: Strahlentherapie und Onkologie | Issue 5/2015

Abstract

Purpose

The purpose of the present study was to evaluate the clinical outcome of CT-guided high-dose-rate brachytherapy (CT-HDRBT) in patients with unresectable hepatocellular carcinoma (HCC).

Patients and methods

Over a 6-year period, 98 patients with 212 unresectable HCC underwent CT-HDRBT applying a ¹⁹²Ir source at our institution. Magnetic resonance imaging (MRI) follow-up was performed 6 weeks after the intervention and then every 3 months. The primary endpoint was local tumor control (LTC); secondary endpoints included progression-free survival (PFS) and overall survival (OS).

Results

Patients were available for MRI evaluation for a mean follow-up of 23.1 months (range 4–64 months; median 20 months). Mean tumor diameter was 5 cm (range 1.8–12 cm). Eighteen of 212 (8.5 %) tumors showed local progression after a mean LTC of 21.1 months. In all, 67 patients (68.4 %) experienced distant tumor progression. The mean PFS was 15.2 months. Forty-six patients died during the follow-up period. Median OS was 29.2 months. Actuarial 1-, 2-, and 3-year OS rates were 80, 62, and 46 %, respectively.

Conclusion

CT-HDRBT is an effective therapy to attain local tumor control in patients with unresectable HCC. Prospective randomized studies comparing CT-HDRBT with the standard treatments like Radiofrequency ablation (RFA) and chemoembolization (TACE) are mandatory.

Maluccio M, Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62:394–399CrossRefPubMed

Bolondi L, Burroughs A, Dufour JF et al (2012) Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 32:348–359PubMed

Forner A, Llovet JM, Bruix J (2010) Hepatocellular carcinoma. Lancet 379:1245–1255CrossRef

Crocetti L, de Baere T, Lencioni R (2010) Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 33:11–17CrossRefPubMedCentralPubMed

Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRefPubMed

Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRefPubMed

Raoul JL, Sangro B, Forner A et al (2011) Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 37:212–220CrossRefPubMed

Ricke J, Wust P (2011) Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol 21:287–293CrossRefPubMed

Ricke J, Wust P, Stohlmann A et al (2004) CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 58:1496–1505CrossRefPubMed

10.

Ricke J, Thormann M, Ludewig M et al (2010) MR-guided liver tumor ablation employing open high-field 1.0 T MRI for image-guided brachytherapy. Eur Radiol 20:1985–1993CrossRefPubMed

11.

Goldberg SN, Grassi CJ, Cardella JF; For the Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-guided Tumor Ablation (2009) Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20:377–390CrossRef

12.

Gil-Alzugaray B, Chopitea A, Iňarrairaegui M et al (2013) Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57:1078–1087CrossRefPubMed

13.

Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRefPubMed

14.

Oliveri RS, Wetterslev J, Gluud C (2011) Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 16:CD004787

15.

Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507CrossRefPubMedCentralPubMed

16.

Cárdenes HR (2009) Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. Clin Transl Oncol 11:276–283CrossRefPubMed

17.

Goodman KA, Wiegner EA, Maturen KE, Zhang Z et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493CrossRefPubMed

18.

Méndez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 45:831–837CrossRefPubMed

19.

Lee SU, Park JW, Kim TH et al (2014) Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol 190:806–814 [Epub ahead of print]CrossRefPubMed

20.

Wang PM, Hsu WC, Chung NN et al (2013) Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments. Strahlenther Onkol 189:301–307CrossRefPubMed

21.

Kim TH, Park JW, Kim YJ et al (2014) Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 190:882–890 [Epub ahead of print]CrossRefPubMed

22.

Jereczek-Fossa BA, Bossi-Zanetti I, Mauro R et al (2013) CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer: a prospective evaluation of 95 patients/118 lesions. Strahlenther Onkol 189:448–455CrossRefPubMed

23.

Bujold A, Massey CA, Kim JJ et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31:1631–1639CrossRefPubMed

24.

Ricke J, Wust P, Wieners G et al (2004) Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol 15:1279–1286CrossRefPubMed

25.

Tselis N, Chatzikonstantinou G, Kolotas C et al (2012) Hypofractionated accelerated computed tomography-guided interstitial high-dose-rate brachytherapy for liver malignancies. Brachytherapy 11:507–514CrossRefPubMed

26.

Collettini F, Schnapauff D, Poellinger A et al (2012) Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (> 7 cm) tumours. Eur Radiol 22:1101–1109CrossRefPubMed

27.

Jung J, Yoon SM, Kim SY et al (2013) Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol 8:249CrossRefPubMedCentralPubMed

28.

Mohnike K, Wieners G, Schwartz F et al (2010) Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 78:172–179CrossRefPubMed

Title: CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma
Authors: Dr. med. Federico Collettini
Nadja Schreiber
Dr. med. Dirk Schnapauff
Priv.-Doz. Dr. med. Timm Denecke
Prof. Dr. med. Peter Wust
Prof. Dr. med. Eckart Schott
Prof. Dr. med. Bernd Hamm
Prof. Dr. med. Bernhard Gebauer
Publication date: 01-05-2015
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 5/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0781-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma

Abstract

Purpose

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2015

Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy

Oligoprogression

8-prenylnaringenin and tamoxifen inhibit the shedding of irradiated epithelial cells and increase the latency period of radiation-induced oral mucositis

Zu empfehlende Dauer der hormonablativen Therapie des lokalisierten Prostatakarzinoms vor Strahlentherapie weiterhin unklar

Hepatotoxicity after liver irradiation in children and adolescents

The SS x-ray unit as an instrument for “total registration” and “race selection”